CHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed the ratings for Allergan plc (formerly known as Actavis plc; NYSE: AGN) and its subsidiaries. The Rating Outlook is Stable. A full list of rating actions, which apply to approximately $44.2 billion of total debt as of March 31, 2015, follows at the end of this release. The affirmations follow Allergan's announcement that it will sell its generic drug manufacturing business to Teva Pharmaceutical Industries Limited (Teva; NYSE: TEVA) for appro